Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen, AbbVie, Takeda, Huadong Medicine  >>  Phase 2
Welcome,         Profile    Billing    Logout  

17 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Elahere (mirvetuximab soravtansine-gynx) / AbbVie
NCT03106077: Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Completed
2
96
US
Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, Folate Receptor Alpha Positive, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
10/19
10/19
2018-004207-39: Mirvetuximab Soravtansine in patients with high expression of folate receptor alpha in their tumor and recurrent ovarian cancer

Not yet recruiting
2
136
Europe
Mirvetuximab Soravtansine, Powder and solvent for concentrate for solution for infusion, Solution for infusion, Capsule, hard, Film-coated tablet, , Caelyx, Carboplatin Kabi, Paclitaxel-GRY®, Gemedac®, Zejula, Lynparza, Rubraca
AGO Research GmbH, ImmunoGen, Inc.
This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-based chemotherapy., Safety and efficacy for carboplatin with Mirvetuximab soravtansine (IMGN853) compared to carboplatin combination chemotherapy, Diseases [C] - Cancer [C04]
 
 
NCT03836157: Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Withdrawn
2
0
US
Mirvetuximab Soravtansine, IMGN853, Bevacizumab
University of Oklahoma, ImmunoGen, Inc.
Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
11/21
05/22
NCT03835819: A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Active, not recruiting
2
18
US
Pembrolizumab, Keytruda, IMGN853, Mirvetuximab soravtansine, Elahere
Dana-Farber Cancer Institute, ImmunoGen, Inc., Merck Sharp & Dohme LLC
Endometrial Cancer
06/24
05/27
NCT03832361: Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Recruiting
2
50
US
IMGN853, mirvetuximab soravtansine
Alessandro Santin, ImmunoGen, Inc.
Endometrial Cancer
10/26
10/28
MIROVA, NCT04274426 / 2018-004207-39: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting
2
136
Europe
Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine
AGO Research GmbH, ImmunoGen, Inc.
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
12/25
12/26
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Hourglass Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC
Hourglass Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer
Hourglass Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC
Hourglass Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer
Completed
2
79
Europe, US, RoW
Mirvetuximab soravtansine, MIRV, IMGN853
AbbVie
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
12/24
12/24
NCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Checkmark Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022
Active, not recruiting
2
125
Europe, Canada, US, RoW
Mirvetuximab soravtansine, MIRV, IGN853, Carboplatin
AbbVie
High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
11/26
11/26
NCT06365853: A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Recruiting
2
100
Europe, Canada, US, RoW
Mirvetuximab Soravtansine, IMGN853, MIRV, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops
AbbVie
Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive
06/26
06/27
2021-003592-34: c Un estudio para probar mirvetuximab soravtansina en mujeres con cánceres epiteliales de ovario, peritoneales primarios o de trompa de Falopio sensibles al platino.

Completed
2
75
Europe
mirvetuximab soravtansine, IMGN853, Concentrate for solution for injection/infusion, Pred Forte
ImmunoGen, Inc., IMMUNOGEN, INC., ImmunoGen, Inc.
Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression Cánceres epiteliales de ovario, peritoneales primarios o de trompa de Falopio recurrentes, sensibles al platino y con alta expresión del receptor de folatos alfa, Cancer of ovary and related organs Cáncer de ovario y órganos afines, Diseases [C] - Cancer [C04]
 
 
NCT06682988: A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Recruiting
2
110
Europe, US, RoW
Mirvetuximab Soravtansine, MIRV, IMGN853
AbbVie
Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube Cancers, High Folate Receptor-Alpha Expression, Platinum Resistant
03/28
03/28
FLORENZA, NCT07059845: A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Recruiting
2
320
RoW
Mirvetuximab Soravtansine, Bevacizumab, Carboplatin
AbbVie
Ovarian Cancer
01/29
01/29
NCT06890338: A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Recruiting
2
140
US
Carboplatin, Mirvetuximab Soravtansine, MIRV, IMGN853, ELAHERE™, Bevacizumab
AbbVie, GOG Foundation
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
02/30
02/30
NCT05887609: An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Recruiting
2
53
US
Mirvetuximab Soravtansine-gynx, IMGN853, MIRV, Olaparib
University of Colorado, Denver, AbbVie
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
01/28
10/28
NCT04606914: Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recruiting
2
70
US
mirvetuximab soravtansine (MIRV; IMGN853)
University of Alabama at Birmingham
Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer
05/26
05/28
KEYNOTE PN409, NCT02606305: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Checkmark Data from FORWARD II trial for ovarian cancer at IGCS 2022
Sep 2022 - Oct 2022: Data from FORWARD II trial for ovarian cancer at IGCS 2022
Checkmark Presentation of P1/2 data in combination with bevacizumab for treatment of ovarian cancer at IGCS 2022
Sep 2022 - Sep 2022: Presentation of P1/2 data in combination with bevacizumab for treatment of ovarian cancer at IGCS 2022
Checkmark Presentation of data from FORWARD II trial for ovarian cancer at IGCS 2022
More
Completed
1/2
264
Europe, Canada, US
Mirvetuximab soravtansine, IMGN853, Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab
ImmunoGen, Inc.
Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
03/21
03/21
TAK-853-1501, NCT06390995: A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

Active, not recruiting
1/2
28
Japan
TAK-853, Mirvetuximab Soravtansine
Takeda
Ovarian Cancer, Solid Tumors
04/25
03/27

Download Options